Preliminary Data Further Show MarzAA’s Potential to Prevent Bleedings
News
Clinical data from the ongoing Phase 2/3 trial data evaluating MarzAA (marzeptacog alfa activated) in patients with Hemophilia A or B with inhibitors continues to demonstrate the treatment’s potential ... Read more